The CeTeG/NOA-09 phase III clinical trial noted that individuals with MGMT-methylated GBM tumors may respond significantly better to a combination of temozolomide and lomustine compared to the use of temozolomide alone [18]. This evidence concerns the gene MGMT and glioblastoma.